CN118984705A - 罗鲁哌酮（roluperidone）在预防精神分裂症患者复发中的用途 - Google Patents
罗鲁哌酮（roluperidone）在预防精神分裂症患者复发中的用途 Download PDFInfo
- Publication number
- CN118984705A CN118984705A CN202380033205.7A CN202380033205A CN118984705A CN 118984705 A CN118984705 A CN 118984705A CN 202380033205 A CN202380033205 A CN 202380033205A CN 118984705 A CN118984705 A CN 118984705A
- Authority
- CN
- China
- Prior art keywords
- patient
- lupai
- luo
- ketone
- schizophrenia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000000980 schizophrenia Diseases 0.000 title claims abstract description 197
- RNRYULFRLCBRQS-UHFFFAOYSA-N roluperidone Chemical compound C1=CC(F)=CC=C1C(=O)CN1CCC(CN2C(C3=CC=CC=C3C2)=O)CC1 RNRYULFRLCBRQS-UHFFFAOYSA-N 0.000 title claims description 9
- 229940121492 roluperidone Drugs 0.000 title claims description 5
- 238000000034 method Methods 0.000 claims abstract description 182
- 208000024891 symptom Diseases 0.000 claims description 344
- 238000011282 treatment Methods 0.000 claims description 189
- 230000000561 anti-psychotic effect Effects 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 33
- 238000013019 agitation Methods 0.000 claims description 28
- 229940079593 drug Drugs 0.000 claims description 28
- 206010020400 Hostility Diseases 0.000 claims description 25
- 230000005032 impulse control Effects 0.000 claims description 24
- 208000019901 Anxiety disease Diseases 0.000 claims description 22
- 230000036506 anxiety Effects 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 22
- 230000000977 initiatory effect Effects 0.000 claims description 20
- 206010042635 Suspiciousness Diseases 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 description 476
- 150000002576 ketones Chemical class 0.000 description 317
- 239000000902 placebo Substances 0.000 description 146
- 229940068196 placebo Drugs 0.000 description 146
- 125000000468 ketone group Chemical group 0.000 description 93
- 230000006872 improvement Effects 0.000 description 50
- 230000000694 effects Effects 0.000 description 47
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 description 39
- 230000008859 change Effects 0.000 description 36
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 35
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 description 34
- 201000010099 disease Diseases 0.000 description 34
- 239000000164 antipsychotic agent Substances 0.000 description 31
- 230000002045 lasting effect Effects 0.000 description 29
- 206010001497 Agitation Diseases 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 25
- 230000006399 behavior Effects 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 25
- 229940005529 antipsychotics Drugs 0.000 description 21
- 238000012216 screening Methods 0.000 description 21
- 208000027418 Wounds and injury Diseases 0.000 description 20
- 208000014674 injury Diseases 0.000 description 20
- 108700028369 Alleles Proteins 0.000 description 16
- 208000011580 syndromic disease Diseases 0.000 description 16
- 230000002996 emotional effect Effects 0.000 description 15
- 230000002459 sustained effect Effects 0.000 description 14
- 208000028017 Psychotic disease Diseases 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000006870 function Effects 0.000 description 12
- 230000008901 benefit Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 9
- 238000012552 review Methods 0.000 description 9
- 230000006866 deterioration Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 208000020016 psychiatric disease Diseases 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 230000007423 decrease Effects 0.000 description 7
- 230000005713 exacerbation Effects 0.000 description 7
- 230000001747 exhibiting effect Effects 0.000 description 7
- 230000003993 interaction Effects 0.000 description 7
- 229940001470 psychoactive drug Drugs 0.000 description 7
- 239000004089 psychotropic agent Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 7
- 208000004547 Hallucinations Diseases 0.000 description 6
- 201000007201 aphasia Diseases 0.000 description 6
- 238000001647 drug administration Methods 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 229960000607 ziprasidone Drugs 0.000 description 6
- 206010002942 Apathy Diseases 0.000 description 5
- 206010012239 Delusion Diseases 0.000 description 5
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 description 5
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 231100000868 delusion Toxicity 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000003291 dopaminomimetic effect Effects 0.000 description 5
- 238000002565 electrocardiography Methods 0.000 description 5
- 230000035558 fertility Effects 0.000 description 5
- 208000006454 hepatitis Diseases 0.000 description 5
- 231100000283 hepatitis Toxicity 0.000 description 5
- 238000010197 meta-analysis Methods 0.000 description 5
- 230000036651 mood Effects 0.000 description 5
- 229960005017 olanzapine Drugs 0.000 description 5
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 229960001534 risperidone Drugs 0.000 description 5
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 5
- 206010001488 Aggression Diseases 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 108090000340 Transaminases Proteins 0.000 description 4
- 102000003929 Transaminases Human genes 0.000 description 4
- 230000016571 aggressive behavior Effects 0.000 description 4
- 229940127236 atypical antipsychotics Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229960004170 clozapine Drugs 0.000 description 4
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000002635 electroconvulsive therapy Methods 0.000 description 4
- 229930195712 glutamate Natural products 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000009097 single-agent therapy Methods 0.000 description 4
- 201000009032 substance abuse Diseases 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000011491 transcranial magnetic stimulation Methods 0.000 description 4
- 230000007384 vagal nerve stimulation Effects 0.000 description 4
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 3
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 3
- 206010001540 Akathisia Diseases 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 3
- 206010010144 Completed suicide Diseases 0.000 description 3
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 3
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010065604 Suicidal behaviour Diseases 0.000 description 3
- 208000012761 aggressive behavior Diseases 0.000 description 3
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 3
- 229960005260 amiodarone Drugs 0.000 description 3
- 229960003036 amisulpride Drugs 0.000 description 3
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical group CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 description 3
- 239000003693 atypical antipsychotic agent Substances 0.000 description 3
- 229940049706 benzodiazepine Drugs 0.000 description 3
- 150000001557 benzodiazepines Chemical class 0.000 description 3
- 229960005123 cariprazine Drugs 0.000 description 3
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 229960002866 duloxetine Drugs 0.000 description 3
- 238000000556 factor analysis Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 206010022437 insomnia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000008520 organization Effects 0.000 description 3
- 208000019906 panic disease Diseases 0.000 description 3
- 229960002296 paroxetine Drugs 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- -1 2- [ [1- [2- (4-fluorophenyl) -2-oxoethyl ] -4-piperidinyl ] methyl ] -2, 3-dihydro-1H-isoindol-1-one hydrochloride hydrate Chemical compound 0.000 description 2
- VOMKSBFLAZZBOW-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-4-oxo-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-9-yl hexadecanoate Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC3=C(C)N=C4N(C3=O)CCCC4OC(=O)CCCCCCCCCCCCCCC)=NOC2=C1 VOMKSBFLAZZBOW-UHFFFAOYSA-N 0.000 description 2
- HOIIHACBCFLJET-SFTDATJTSA-N 4-((6br,10as)-3-methyl-2,3,6b,9,10,10a-hexahydro-1h-pyrido-[3',4':4,5]-pyrrolo[1,2,3-de]quinoxalin-8-(7h)-yl)-1-(4-fluorophenyl)-1-butanone Chemical compound C([C@@H]1N2CCN(C=3C=CC=C(C2=3)[C@@H]1C1)C)CN1CCCC(=O)C1=CC=C(F)C=C1 HOIIHACBCFLJET-SFTDATJTSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010011971 Decreased interest Diseases 0.000 description 2
- 208000002091 Febrile Seizures Diseases 0.000 description 2
- 208000021663 Female sexual arousal disease Diseases 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 2
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 206010041243 Social avoidant behaviour Diseases 0.000 description 2
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 2
- 208000018452 Torsade de pointes Diseases 0.000 description 2
- 208000002363 Torsades de Pointes Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000009798 acute exacerbation Effects 0.000 description 2
- 102000030619 alpha-1 Adrenergic Receptor Human genes 0.000 description 2
- 108020004102 alpha-1 Adrenergic Receptor Proteins 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229960001948 caffeine Drugs 0.000 description 2
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960001076 chlorpromazine Drugs 0.000 description 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- NSNHWTBQMQIDCF-UHFFFAOYSA-N dihydrate;hydrochloride Chemical compound O.O.Cl NSNHWTBQMQIDCF-UHFFFAOYSA-N 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000003777 experimental drug Substances 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 208000004731 long QT syndrome Diseases 0.000 description 2
- 229950003467 lumateperone Drugs 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 230000008450 motivation Effects 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 230000003557 neuropsychological effect Effects 0.000 description 2
- 229940005483 opioid analgesics Drugs 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 229960000635 paliperidone palmitate Drugs 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229960000762 perphenazine Drugs 0.000 description 2
- 108010025593 phenylalanine (histidine) aminotransferase Proteins 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 238000009597 pregnancy test Methods 0.000 description 2
- 238000002203 pretreatment Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 229960004431 quetiapine Drugs 0.000 description 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229960000652 sertindole Drugs 0.000 description 2
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 229960004496 zotepine Drugs 0.000 description 2
- HDOZVRUNCMBHFH-UHFFFAOYSA-N zotepine Chemical compound CN(C)CCOC1=CC2=CC=CC=C2SC2=CC=C(Cl)C=C12 HDOZVRUNCMBHFH-UHFFFAOYSA-N 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 208000007415 Anhedonia Diseases 0.000 description 1
- 206010002652 Anorgasmia Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 101150010738 CYP2D6 gene Proteins 0.000 description 1
- 101150022946 CYP3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 101100137368 Dictyostelium discoideum cypD gene Proteins 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000027776 Extrapyramidal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101150104779 HTR2A gene Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000000543 Histamine Receptors Human genes 0.000 description 1
- 108010002059 Histamine Receptors Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 201000006347 Intellectual Disability Diseases 0.000 description 1
- 206010022524 Intentional self-injury Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 1
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 101150009380 PPIF gene Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 102100034943 Peptidyl-prolyl cis-trans isomerase F, mitochondrial Human genes 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 101100222691 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CPR3 gene Proteins 0.000 description 1
- 101100276454 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYC7 gene Proteins 0.000 description 1
- 208000036752 Schizophrenia, paranoid type Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 102100028662 Sigma intracellular receptor 2 Human genes 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 206010042464 Suicide attempt Diseases 0.000 description 1
- 208000037114 Symptom Flare Up Diseases 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229960001210 brexpiprazole Drugs 0.000 description 1
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 150000003950 cyclic amides Chemical class 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001544 dysphoric effect Effects 0.000 description 1
- 230000006397 emotional response Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000742 histaminergic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- XTBAPWCYTNCZTO-UHFFFAOYSA-N isoindol-1-one Chemical compound C1=CC=C2C(=O)N=CC2=C1 XTBAPWCYTNCZTO-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000036630 mental development Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 229960001797 methadone Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940054010 other antipsychotics in atc Drugs 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 229940097325 prolactin Drugs 0.000 description 1
- 229960003598 promazine Drugs 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 108010040167 sigma-2 receptor Proteins 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309874P | 2022-02-14 | 2022-02-14 | |
| US63/309,874 | 2022-02-14 | ||
| PCT/US2023/062500 WO2023154927A1 (en) | 2022-02-14 | 2023-02-13 | Use of roluperidone in preventing relapse in schizophrenia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118984705A true CN118984705A (zh) | 2024-11-19 |
Family
ID=85569991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380033205.7A Pending CN118984705A (zh) | 2022-02-14 | 2023-02-13 | 罗鲁哌酮（roluperidone）在预防精神分裂症患者复发中的用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230255953A1 (https=) |
| EP (2) | EP4479049B1 (https=) |
| JP (1) | JP2025505261A (https=) |
| KR (1) | KR20240161650A (https=) |
| CN (1) | CN118984705A (https=) |
| AU (1) | AU2023217097A1 (https=) |
| CA (1) | CA3243767A1 (https=) |
| CL (1) | CL2024002418A1 (https=) |
| ES (1) | ES3064313T3 (https=) |
| IL (1) | IL314859A (https=) |
| MX (1) | MX2024009828A (https=) |
| WO (1) | WO2023154927A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| WO2020264486A1 (en) * | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
-
2023
- 2023-02-13 EP EP23710619.0A patent/EP4479049B1/en active Active
- 2023-02-13 JP JP2024547680A patent/JP2025505261A/ja active Pending
- 2023-02-13 AU AU2023217097A patent/AU2023217097A1/en active Pending
- 2023-02-13 US US18/168,028 patent/US20230255953A1/en active Pending
- 2023-02-13 WO PCT/US2023/062500 patent/WO2023154927A1/en not_active Ceased
- 2023-02-13 EP EP25223916.5A patent/EP4729122A2/en active Pending
- 2023-02-13 KR KR1020247031088A patent/KR20240161650A/ko active Pending
- 2023-02-13 IL IL314859A patent/IL314859A/en unknown
- 2023-02-13 CA CA3243767A patent/CA3243767A1/en active Pending
- 2023-02-13 CN CN202380033205.7A patent/CN118984705A/zh active Pending
- 2023-02-13 ES ES23710619T patent/ES3064313T3/es active Active
-
2024
- 2024-08-12 CL CL2024002418A patent/CL2024002418A1/es unknown
- 2024-08-12 MX MX2024009828A patent/MX2024009828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3243767A1 (en) | 2023-08-17 |
| WO2023154927A1 (en) | 2023-08-17 |
| EP4479049B1 (en) | 2025-12-17 |
| US20230255953A1 (en) | 2023-08-17 |
| EP4729122A2 (en) | 2026-04-22 |
| JP2025505261A (ja) | 2025-02-21 |
| IL314859A (en) | 2024-10-01 |
| AU2023217097A1 (en) | 2024-08-29 |
| CL2024002418A1 (es) | 2024-12-13 |
| EP4479049A1 (en) | 2024-12-25 |
| ES3064313T3 (en) | 2026-04-23 |
| MX2024009828A (es) | 2024-11-08 |
| KR20240161650A (ko) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lembo et al. | AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea | |
| Bell et al. | Medication treatment of opioid use disorder | |
| Khoromi et al. | Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain | |
| Lieberman et al. | Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | |
| Bostwick | A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy | |
| Krupitsky et al. | Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia | |
| Reynolds III et al. | Assessment and treatment of major depression in older adults | |
| Findling et al. | An open-label pilot study of St. John's wort in juvenile depression | |
| HK1252658A1 (zh) | 治疗炎症或神经性疼痛的方法 | |
| Castle et al. | Physical health and schizophrenia | |
| Kato et al. | Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT | |
| Rosenberg et al. | Clinical application of operationalized criteria for ‘Depression of Alzheimer's Disease’ | |
| Addolorato et al. | Safety and compliance of long-term low-dose ondansetron in alcohol use disorder treatment. | |
| de los Cobos et al. | A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence | |
| CN118984705A (zh) | 罗鲁哌酮（roluperidone）在预防精神分裂症患者复发中的用途 | |
| Van Beusekom et al. | A review of recent advances in knowledge about methadone maintenance treatment | |
| Özdener et al. | Eluxadoline in the treatment of diarrhea-predominant irritable bowel syndrome | |
| Madlung‐Kratzer et al. | A double‐blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow‐release oral morphine versus methadone in opioid‐dependent in‐patients willing to undergo detoxification | |
| Harris et al. | Obsessive‐compulsive disorder: current management options | |
| Schmitt et al. | Results of a phase Ib study of SB-121, an investigational probiotic formulation, in participants with autism spectrum disorder | |
| Avari et al. | Pharmacologic-enhanced approaches for the anxiety disorders | |
| Meschia et al. | Mayo Acute Stroke Trial for Enhancing Recovery (MASTER) protocol | |
| Gagal et al. | Comparative efficacy of on-demand Sildenafil, Tadalafil and daily Tadalafil for treatment of erectile dysfunction: A 12-week randomized controlled study | |
| Kandula | Characterizing Adverse Effects and Risk Factors in Multidrug Tuberculosis Regimens: Implications for Personalized Treatment Protocols | |
| HK40089955A (zh) | 治疗与阿尔茨海默氏病相关的激越的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |